Oral LD50 in rat is 7060 mg/kg. Oral LD50 in mouse is 3450 mg/kg.
A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The serum concentration of Stanolone can be increased when it is combined with Prasterone. |
| Cyclosporine | The risk or severity of liver damage can be increased when Stanolone is combined with Cyclosporine. |
| Insulin human | Stanolone may increase the hypoglycemic activities of Insulin human. |
| Insulin lispro | Stanolone may increase the hypoglycemic activities of Insulin lispro. |
| Insulin glargine | Stanolone may increase the hypoglycemic activities of Insulin glargine. |
| Insulin pork | Stanolone may increase the hypoglycemic activities of Insulin pork. |
| Troglitazone | Stanolone may increase the hypoglycemic activities of Troglitazone. |
| Glimepiride | Stanolone may increase the hypoglycemic activities of Glimepiride. |
| Sulfisoxazole | Stanolone may increase the hypoglycemic activities of Sulfisoxazole. |
| Disopyramide | Stanolone may increase the hypoglycemic activities of Disopyramide. |
| Acarbose | Stanolone may increase the hypoglycemic activities of Acarbose. |
| Metformin | Stanolone may increase the hypoglycemic activities of Metformin. |
| Sulfadiazine | Stanolone may increase the hypoglycemic activities of Sulfadiazine. |
| Rosiglitazone | Stanolone may increase the hypoglycemic activities of Rosiglitazone. |
| Acetohexamide | Stanolone may increase the hypoglycemic activities of Acetohexamide. |
| Quinine | Stanolone may increase the hypoglycemic activities of Quinine. |
| Miglitol | Stanolone may increase the hypoglycemic activities of Miglitol. |
| Chlorpropamide | Stanolone may increase the hypoglycemic activities of Chlorpropamide. |
| Nateglinide | Stanolone may increase the hypoglycemic activities of Nateglinide. |
| Pentamidine | Stanolone may increase the hypoglycemic activities of Pentamidine. |
| Mifepristone | Stanolone may increase the hypoglycemic activities of Mifepristone. |
| Tolazamide | Stanolone may increase the hypoglycemic activities of Tolazamide. |
| Repaglinide | Stanolone may increase the hypoglycemic activities of Repaglinide. |
| Phenformin | Stanolone may increase the hypoglycemic activities of Phenformin. |
| Sulfamethoxazole | Stanolone may increase the hypoglycemic activities of Sulfamethoxazole. |
| Glyburide | Stanolone may increase the hypoglycemic activities of Glyburide. |
| Glipizide | Stanolone may increase the hypoglycemic activities of Glipizide. |
| Gliclazide | Stanolone may increase the hypoglycemic activities of Gliclazide. |
| Tolbutamide | Stanolone may increase the hypoglycemic activities of Tolbutamide. |
| Pioglitazone | Stanolone may increase the hypoglycemic activities of Pioglitazone. |
| Bromocriptine | Stanolone may increase the hypoglycemic activities of Bromocriptine. |
| Gliquidone | Stanolone may increase the hypoglycemic activities of Gliquidone. |
| Mitiglinide | Stanolone may increase the hypoglycemic activities of Mitiglinide. |
| Sitagliptin | Stanolone may increase the hypoglycemic activities of Sitagliptin. |
| Sunitinib | Stanolone may increase the hypoglycemic activities of Sunitinib. |
| Exenatide | Stanolone may increase the hypoglycemic activities of Exenatide. |
| Mecasermin | Stanolone may increase the hypoglycemic activities of Mecasermin. |
| Pramlintide | Stanolone may increase the hypoglycemic activities of Pramlintide. |
| Glisoxepide | Stanolone may increase the hypoglycemic activities of Glisoxepide. |
| Insulin aspart | Stanolone may increase the hypoglycemic activities of Insulin aspart. |
| Insulin detemir | Stanolone may increase the hypoglycemic activities of Insulin detemir. |
| Insulin glulisine | Stanolone may increase the hypoglycemic activities of Insulin glulisine. |
| Glymidine | Stanolone may increase the hypoglycemic activities of Glymidine. |
| AICA ribonucleotide | Stanolone may increase the hypoglycemic activities of AICA ribonucleotide. |
| Buformin | Stanolone may increase the hypoglycemic activities of Buformin. |
| Vildagliptin | Stanolone may increase the hypoglycemic activities of Vildagliptin. |
| Voglibose | Stanolone may increase the hypoglycemic activities of Voglibose. |
| NN344 | Stanolone may increase the hypoglycemic activities of NN344. |
| AMG-222 | Stanolone may increase the hypoglycemic activities of AMG-222. |
| Bisegliptin | Stanolone may increase the hypoglycemic activities of Bisegliptin. |
| Alogliptin | Stanolone may increase the hypoglycemic activities of Alogliptin. |
| Dapagliflozin | Stanolone may increase the hypoglycemic activities of Dapagliflozin. |
| Saxagliptin | Stanolone may increase the hypoglycemic activities of Saxagliptin. |
| Liraglutide | Stanolone may increase the hypoglycemic activities of Liraglutide. |
| Gosogliptin | Stanolone may increase the hypoglycemic activities of Gosogliptin. |
| Linagliptin | Stanolone may increase the hypoglycemic activities of Linagliptin. |
| Canagliflozin | Stanolone may increase the hypoglycemic activities of Canagliflozin. |
| Glibornuride | Stanolone may increase the hypoglycemic activities of Glibornuride. |
| Benfluorex | Stanolone may increase the hypoglycemic activities of Benfluorex. |
| Empagliflozin | Stanolone may increase the hypoglycemic activities of Empagliflozin. |
| Albiglutide | Stanolone may increase the hypoglycemic activities of Albiglutide. |
| Dulaglutide | Stanolone may increase the hypoglycemic activities of Dulaglutide. |
| Lobeglitazone | Stanolone may increase the hypoglycemic activities of Lobeglitazone. |
| Netoglitazone | Stanolone may increase the hypoglycemic activities of Netoglitazone. |
| Rivoglitazone | Stanolone may increase the hypoglycemic activities of Rivoglitazone. |
| Ciglitazone | Stanolone may increase the hypoglycemic activities of Ciglitazone. |
| Lixisenatide | Stanolone may increase the hypoglycemic activities of Lixisenatide. |
| Insulin beef | Stanolone may increase the hypoglycemic activities of Insulin beef. |
| Insulin degludec | Stanolone may increase the hypoglycemic activities of Insulin degludec. |
| Insulin peglispro | Stanolone may increase the hypoglycemic activities of Insulin peglispro. |
| Insulin tregopil | Stanolone may increase the hypoglycemic activities of Insulin tregopil. |
| Ipragliflozin | Stanolone may increase the hypoglycemic activities of Ipragliflozin. |
| Dutogliptin | Stanolone may increase the hypoglycemic activities of Dutogliptin. |
| Allicin | Stanolone may increase the hypoglycemic activities of Allicin. |
| Tofogliflozin | Stanolone may increase the hypoglycemic activities of Tofogliflozin. |
| Ertugliflozin | Stanolone may increase the hypoglycemic activities of Ertugliflozin. |
| 2,4-thiazolidinedione | Stanolone may increase the hypoglycemic activities of 2,4-thiazolidinedione. |
| Teneligliptin | Stanolone may increase the hypoglycemic activities of Teneligliptin. |
| Omarigliptin | Stanolone may increase the hypoglycemic activities of Omarigliptin. |
| Carmegliptin | Stanolone may increase the hypoglycemic activities of Carmegliptin. |
| Gemigliptin | Stanolone may increase the hypoglycemic activities of Gemigliptin. |
| Anagliptin | Stanolone may increase the hypoglycemic activities of Anagliptin. |
| Evogliptin | Stanolone may increase the hypoglycemic activities of Evogliptin. |
| Sotagliflozin | Stanolone may increase the hypoglycemic activities of Sotagliflozin. |
| Balaglitazone | Stanolone may increase the hypoglycemic activities of Balaglitazone. |
| Remogliflozin etabonate | Stanolone may increase the hypoglycemic activities of Remogliflozin etabonate. |
| Carbutamide | Stanolone may increase the hypoglycemic activities of Carbutamide. |
| Guar gum | Stanolone may increase the hypoglycemic activities of Guar gum. |
| Metahexamide | Stanolone may increase the hypoglycemic activities of Metahexamide. |
| Semaglutide | Stanolone may increase the hypoglycemic activities of Semaglutide. |
| Taspoglutide | Stanolone may increase the hypoglycemic activities of Taspoglutide. |
| Englitazone | Stanolone may increase the hypoglycemic activities of Englitazone. |
| Tirzepatide | Stanolone may increase the hypoglycemic activities of Tirzepatide. |
| Gastric inhibitory polypeptide | Stanolone may increase the hypoglycemic activities of Gastric inhibitory polypeptide. |
| Dextrose, unspecified form | The serum concentration of Dextrose, unspecified form can be decreased when it is combined with Stanolone. |
| Propranolol | Stanolone may increase the excretion rate of Propranolol which could result in a lower serum level and potentially a reduction in efficacy. |
| Flunisolide | The risk or severity of edema formation can be increased when Stanolone is combined with Flunisolide. |
| Beclomethasone dipropionate | The risk or severity of edema formation can be increased when Stanolone is combined with Beclomethasone dipropionate. |
| Betamethasone | The risk or severity of edema formation can be increased when Stanolone is combined with Betamethasone. |
| Desoximetasone | The risk or severity of edema formation can be increased when Stanolone is combined with Desoximetasone. |